Jointly, these data imply that coexisting mutations in EGFR itself or in other cancer-drivers at baseline may potentially impair the efficacy of EGFR-TKIs and explain why some TKI-treated NSCLCs are intrinsically resistant [18]. Here, EGFR is linked to cancer.